anyETF
New ETF
$SNFL

Cold Season ETF

When everyone's sneezing, your portfolio is wheezing... to the bank.

+$285.70 (+2.86%)Past 5 years
$10,000 invested in $SNFL
Yearly return
average since Jan 1996
Beat the S&P 500
by this much a year
Biggest drop
from its high, 2021–2023
Holdings
bigger names weigh more, max 25%

The backtest starts in Jan 1996, as far back as our price data goes. Companies that went public later join the quarter after their IPO, like Sanofi ADS in 2002.

Criteria

  1. 1The company makes vaccines or drugs for flu, cold, or respiratory illness.
  2. 2The company is likely to see increased demand from a seasonal illness surge.

Composition

AZN−5%GILD+34%PFE+10%SNY−16%MRNA+570%KVUE+16%BNTX−7%AMRX+95%PRGONVAX
Size is weight, color is the past year’s return.−30%+30%

Holdings

CompanyWeight